EyePoint Pharmaceuticals
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, EyePoint Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).
EyePoint Pharmaceuticals: 16 sponsored US clinical trials, 3 recruiting.
EyePoint Pharmaceuticals sponsors 16 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 9 completed. 8 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diabetic Macular Edema, with 3 trials.
Top-decile sponsor footprint
EyePoint Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
9 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
16 total, page 1 of 1
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449936
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449923
Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
NCT05191706
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
NCT06683742
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
NCT06668064
Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)
NCT06099184
Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)
NCT05383209
Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)
NCT05381948
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert
NCT05070728
First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)
NCT04747197
Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
NCT04511650
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
NCT04405245
DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001
NCT04290676
The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
NCT03197870
Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis
NCT02748512
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
NCT01694186
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 6 |
| Phase 3 | 7 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the EyePoint Pharmaceuticals pipeline
3 recruiting of 16 indexed (19% open); 9 completed (56%).
Phase mix: 8 late (III/IV) vs 7 early (I/II) (balanced across stages).
Top condition: Diabetic Macular Edema (3 trials), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
EyePoint Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 16 registered trials and 19% open enrollment, not the therapeutic-area sidebar.
EyePoint Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 16 trials (± recruiting share)
- Accelerated Community Oncology Research Network · 16 trials · 0% recruiting
- Altimmune · 16 trials · 6% recruiting
- American University · 16 trials · 13% recruiting
- Anthera Pharmaceuticals · 16 trials · 0% recruiting
Sponsors near 19% open enrollment (± trial volume)
- Hebrew SeniorLife · 19% recruiting · 32 trials
- Insulet Corporation · 19% recruiting · 16 trials
- University of California, Davis · 19% recruiting · 657 trials
- Medical University of South Carolina · 19% recruiting · 755 trials
Related
What to do with this EyePoint Pharmaceuticals page
16 registered trials is a research-attention snapshot, not an endorsement of EyePoint Pharmaceuticals or any single study.
- 3 of EyePoint Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Diabetic Macular Edema is the condition EyePoint Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetic Macular Edema trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
EyePoint Pharmaceuticals pipeline card: 16 registered trials from official public datasets.Report a data error.